Quinolone Analog Synthesis via Segmented Cyclic Intermediates

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods lack effective compounds that can inhibit cell proliferation and induce apoptosis while stabilizing quadruplex structures, which are crucial for treating cell proliferative disorders such as cancer and microbial infections.

Innovation Solution

The development of quinolone analogs through specific synthetic methods, involving the reaction of compounds with particular structures and bases in the presence of Lewis acids, to produce compounds that can interact with DNA quadruplexes and exert therapeutic effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods are used to prepare compounds, then the synthesis process is simple, but the compounds cannot effectively inhibit cell proliferation and induce apoptosis while stabilizing quadruplex structures

Engineering Contradiction:
Improvetherapeutic effectivenessVSAvoidsynthetic method complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The synthesis is divided into multiple discrete steps: (1) forming a cyclic intermediate by reacting a compound of formula (6A)-(6C) with a compound of formula (7) in the presence of a base, (2) treating the cyclic intermediate with a Lewis acid to form an intermediate product, and (3) reacting the intermediate product with an amine to produce the final quinolone analog. This segmented approach enables precise control over the synthesis process to achieve the desired therapeutic effectiveness.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The method employs preliminary formation of the cyclic intermediate structure before introducing the amine substituent. The cyclic intermediate is prepared first through condensation reaction, then treated with Lewis acid to activate it, and finally reacted with the amine. This preliminary action ensures the core structure is properly formed and activated before the final functional group introduction, achieving reliable therapeutic compounds.

Inventive Principle:
Principle #10Preliminary action

2Stability of the object's composition

If specific synthetic methods with bases and Lewis acids are used, then quinolone analogs can stabilize quadruplex structures and induce apoptosis, but the manufacturing process becomes more complex

Engineering Contradiction:
Improvequadruplex structure stabilizationVSAvoidsynthesis ease
Core Design Contradiction:
Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

The synthesis method utilizes specific parameter changes including: (1) controlling pH by adding base to deprotonate the hydroxyl group of compound (6A)-(6C), (2) using Lewis acids with specific coordination properties to activate the cyclic intermediate, and (3) selecting amines with specific nucleophilicity. These parameter changes enable the formation of quinolone analogs with quadruplex-stabilizing properties while providing a systematic manufacturing approach.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The method employs intermediate compounds as mediators in the synthesis pathway. The cyclic intermediate formed from compounds (6A)-(6C) and (7) serves as a mediator that carries the core structure, which is then activated by Lewis acid and finally coupled with the amine. This intermediary approach allows complex molecular assembly through manageable steps, balancing manufacturing feasibility with the achievement of quadruplex stabilization.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If quinolone analogs are synthesized to inhibit cell proliferation, then therapeutic activity is achieved, but the production time and process steps increase

Engineering Contradiction:
Improvecell proliferation inhibitionVSAvoidsynthesis time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The synthesis method employs continuous useful action by: (1) conducting the condensation reaction of compounds (6A)-(6C) with compound (7) in the presence of base to continuously form the cyclic intermediate, (2) immediately treating the cyclic intermediate with Lewis acid to maintain reaction momentum and form the activated intermediate, and (3) continuously reacting with the amine to produce the final quinolone analog. This continuous process minimizes idle time between steps and maintains productive reaction flow, reducing overall synthesis time while ensuring reliable cell proliferation inhibition activity.

Inventive Principle:
Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The synthesized quinolone analogs effectively inhibit cell proliferation, induce apoptosis, and stabilize quadruplex structures, offering potential treatments for cancer and microbial infections by modulating oncogene expression and disrupting viral replication.

Implementation Method 1

contacting a compound having formula (6A), (6B) or (6C) with a compound having formula (7) or tautomers thereof in the presence of a base

Methodology Applied
Scientific EffectDeprotonation:

Implementation Method 2

the anion (reactive intermediate) can be generated under more mild conditions and reacted with the other reactant

Methodology Applied
Scientific EffectNucleophilic attack:

Implementation Method 3

the use of a co-ordinating metal or acid allows the hydrogen on the α-carbon in formula (7) and (10) to become more acidic, thus facilitating its removal by a weak base

Methodology Applied
Scientific EffectLewis acid coordination:

Implementation Method 4

The coordinating metal then orientates (holds) the resulting products in a conformation which facilitates the second bond formation

Methodology Applied
Scientific EffectActivation of intermediate:

Data Source

PatentEP1928887B1Methods of preparing quinolone analogs
Publication Date: 2014.12.17 SENHWA BIOSCIENCES INC
  • EP1928887B1 patent drawing
  • EP1928887B1 patent drawing
  • EP1928887B1 patent drawing

AI summary

The present invention relates to the preparation of compounds which are capable of inducing cell death such as apoptotic ceil death (apoptosis), and /or for reducing a cell proliferative disorder, of the formula (I) and structurally closeby related compounds.